Please assess the completion status of the following clinical trial:

Trial Title: Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of moderate to severe plaque-type psoriasis and have had participated in Study P05319.~* Subjects must have demonstrated an adequate but suboptimal response to infliximab in Study P05319~* Subjects must be at least 18 years old~* Subjects must be candidates for phototherapy or systemic treatment for psoriasis.~* Subjects must not be pregnant and must meet contraceptive requirements~* Subjects must meet tuberculosis screening criteria~* Subjects must meet laboratory and medical history screening requirements~Exclusion Criteria:~* Subjects for whom infliximab or methotrexate is contraindicated or not recommended.~* Subjects already using certain investigational, biological, or immunosuppressive drugs~* Subjects with certain comorbid conditions~* Subjects who currently have or have a history of certain infections~* Subjects who have recently received live virus or bacterial vaccinations~* Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IFX q 6 weeks (Type: EXPERIMENTAL): None
- IFX + MTX (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).